{"schema_version":"secwatch.filing_event.v1","accession":"0001077183-22-000047","form_type":"8-K","ticker":"NEO","cik":"0001077183","company_name":"NEOGENOMICS INC","filed_at":"2022-03-09T23:59:59+00:00","discovered_at":"2026-05-14T18:04:05.349220+00:00","generated_at":"2026-06-27T00:17:45.348937+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"NeoGenomics announces retirement of COO Cardoza; appoints Sholehvar as President of Clinical Services","bullets":["George Cardoza, President and COO Lab Ops, to retire effective March 31, 2022.","Dr. Steven Brodie appointed interim President of Lab Operations.","Dr. David Sholehvar appointed President, Clinical Services, effective March 14, 2022.","Sholehvar compensation: $435K base, 50% bonus, $750K equity grant."],"urls":{"canonical":"https://secwatch.observer/filing/0001077183-22-000047","json":"https://secwatch.observer/filing/0001077183-22-000047.json","markdown":"https://secwatch.observer/filing/0001077183-22-000047.md","text":"https://secwatch.observer/filing/0001077183-22-000047.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1077183/000107718322000047/0001077183-22-000047-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1077183/000107718322000047/neo-20220309.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T00:17:45.348937+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2e00565a91","claim":"David Sholehvar was appointed as President, Clinical Services Division at NEOGENOMICS INC.","evidence_excerpt":"Dr. David Sholehvar, age 54, was appointed President, Clinical Services Division of the Company, effective March 14, 2022","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1077183/000107718322000047/0001077183-22-000047-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President, Clinical Services Division"}],"fact_type":"executive_change"},{"claim_id":"58279b94e9","claim":"George A. Cardoza departed as President and Chief Operating Officer, Laboratory Operations at NEOGENOMICS INC.","evidence_excerpt":"George A. Cardoza, NeoGenomics, Inc.’s (the “Company”) current President and Chief Operating Officer, Laboratory Operations, informed the Company of his intention to retire from his role effective March 31, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1077183/000107718322000047/0001077183-22-000047-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"retire"},{"label":"Role","value":"President and Chief Operating Officer, Laboratory Operations"}],"fact_type":"executive_change"},{"claim_id":"d6da562eec","claim":"Steven Brodie was appointed as interim President of Lab Operations at NEOGENOMICS INC.","evidence_excerpt":"Dr. Steven Brodie, the Company’s current Senior Vice President, Laboratory Operations, has been appointed the Company’s interim President of Lab Operations.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1077183/000107718322000047/0001077183-22-000047-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"interim President of Lab Operations"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}